After asking industry leaders about all the issues we thought would matter most in 2015, we asked them what questions they thought we had missed. Here is what they told […]
HealthPrize Technologies, a medication adherence and digital patient engagement company, has announced positive results from a number of pharmaceutical company sponsored patient support programs conducted across a variety of […]
The executive leadership and senior management team switches are expected to aid growth after the Auxilium acquisition. As Endo International plc prepares to acquire Aux-ilium, the company has announced […]
By Jeff Greene If you’re a successful pharmaceutical marketing agency in 2015, you’re faced with a conundrum: • It’s getting harder for your clients to promote their products to physicians […]
• According to a survey by TechnologyAdvice Research (technologyadvice.com), 60.8 percent of patients say digital services play an important role when choosing a physician. Less than one-third of patients surveyed […]
The global EPO market is expected to reach $11.9 billion by 2020, with promising CAGR of 9.7 percentfrom 2014 to 2020, according to a report by Allied Market Research (alliedmarketresearch.com). […]
Princeton, NJ – June 28, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense […]
FDA Grants Genentech’s Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Announcement Follows FDA Breakthrough Therapy Designation for GA101 in CLL FDA Decision on the GA101 Biologics […]
HIV Positive Men Show No Signs of HIV after Bone Marrow Transplant and Discontinuation of Anti-Retroviral Therapy Boston, MA – Two Brigham and Women’s Hospital patients with longstanding HIV infections […]
Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer’s disease Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer’s; 24-week […]
